Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023
Cancer Causes & Control · 2025
DOI: 10.1007/s10552-025-01959-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Causes & Control, 2025. Verfasst von Lisa Gallicchio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA. lisa.ga…. Hauptthemen laut MEDLINE: National Institutes of Health (U.S.), Neoplasms, Cancer Survivors, Rare Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Purpose
Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.
Methods
Newly awarded grants focused on rare cancers in the NIH cancer survivorship research portfolio from Fiscal Year (FY) 2017 to FY2023 were identified. Grant characteristics were abstracted and described. In addition, the number of grants for each rare cancer type was mapped to current Surveillance, Epidemiology, and End Results program incidence and relative survival rates.
Results
A total of 93 survivorship grants focused on one or multiple rare cancer types were funded from FY2017 to FY2023. Approximately 85% of these grants investigated one of four cancer types: leukemia, head & neck, ovarian and brain. Few grants focused on other rare cancer types, such as multiple myeloma (n = 5), testicular cancer (n = 3), rectal cancer (n = 1), thyroid cancer (n = 1), and cervical cancer (n = 0). About half of the grants (50.5%) were observational studies; 34.4% focused explicitly on pediatric cancer survivors.
Conclusions
Survivorship research for many rare cancer types is limited. This paucity of research is a barrier to the identification of survivorship needs and the development of interventions to address these needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA. lisa.gallicchio@nih.gov.
- National Cancer Institute, 9609 Medical Center Drive, Rockville, MD, 20850, USA. lisa.gallicchio@nih.gov.
- Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
- Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
- Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Förderung
- National Cancer Institute
Zitieren
APA
Gallicchio, L., Mollica, M., Tesauro, G., Doose, M., Guida, J. L., Maher, M. E., & Tonorezos, E. (2025). Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023. Cancer Causes & Control. https://doi.org/10.1007/s10552-025-01959-8
Vancouver
Gallicchio L, Mollica M, Tesauro G, Doose M, Guida JL, Maher ME, et al. Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023. Cancer Causes & Control. 2025. doi:10.1007/s10552-025-01959-8
BibTeX
@article{Gallicchio2025,
author = {Gallicchio, Lisa and Mollica, Michelle and Tesauro, Gina and Doose, Michelle and Guida, Jennifer L and Maher, Molly E and Tonorezos, Emily},
title = {Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023},
journal = {Cancer Causes & Control},
year = {2025},
doi = {10.1007/s10552-025-01959-8}
}
EUVIMED